Tools for flow cytometry.
Intelligent Gating Tool
AI-enabled gating assistance for flow cytometry analysis. Define hierarchical gating strategies, annotate populations, and generate reproducible gating reports — without the tedium.
- Define hierarchical gating strategies, annotate populations, and generate reproducible gating reports
- Export-ready gating trees with metadata annotations
- Supports common immune phenotyping panels (T cell, NK, DC, myeloid)
Immune Panel Builder
Smart spectral unmixing and panel design for multicolor flow cytometry.
- Avoid fluorochrome conflicts, optimize reagent combinations for your laser config, and validate panels against known co-expression profiles
- Fluorochrome compatibility checker across common cytometer configs
- Clone and antibody suggestions ranked by literature usage
Basic immunology.
Drug discovery.
Clinical translation.
Director-level immunologist with 15 years of experience across early-stage drug discovery, vaccine development, and clinical translation. Specializing in target identification, mechanism of action studies, and building the translational evidence packages that advance novel assets from bench to first-in-human.
Methods and Compositions for Treatment of Cancer and Infectious Diseases
Methods for Treatment of Bladder Cancer
STING Agonist Combination Therapies with Checkpoint Inhibitors
Novel Antibody Drug Conjugate (ADC) — IO Target
Novel Immune Checkpoint Antibody — New Targets Program
Patents span STING agonist programs at Aduro Biotech and novel IO antibody targets at Tizona Therapeutics. See Google Patents ↗ for additional filings.
I am a Director-level immunologist with over a decade of drug discovery experience spanning innate immune signaling, immuno-oncology, and age-related disease. I have built and led research teams at multiple biotech companies, consistently bridging rigorous preclinical science with translational program strategy.
At Aduro Biotech, I was a core contributor to the STING agonist program, helping develop ADU-S100 (MIW815) from mechanistic research through Phase I clinical trial design — including dose selection and interpretation of clinical results. At Tizona Therapeutics, I led both the translational team for a lead clinical asset and a new targets program identifying and validating novel immunology ideas.
Most recently, as Director of Immunology at Deciduous Therapeutics, I built the immunology function from the ground up, advancing redosable iNKT-based drug candidates and leading the team through high-complexity in vitro and in vivo programs. Across these roles I've been known for exceptional flow cytometry expertise — panel design, high-throughput data analysis, and implementing new analytical platforms — and for mentoring scientists at every career stage.